Moumita Basu Email

Scientist-III . ImmunoACT

Current Roles

Employees:
179
Revenue:
$27.7M
About
Spun-out from IIT-Bombay in 2018, ImmunoACT is India's pioneer of Gene-modified Cell Therapies, having launched the country's first CAR-T cell therapy for treatment of certain B-cell malignancies. With a rapidly expanding pipeline beginning, our mission is to provide affordable access to novel CAR-T cell therapies.
ImmunoACT Address

Navi Mumbai, null
IN
ImmunoACT Email